相关实验视频
Updated: Jan 7, 2026

06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
2.0K
血管内脑计算机接口在阿尔茨海默病患者中的应用
Yuhao Sun1, Danyang Chen1, Qing Ye2
1Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Research (Washington, D.C.)
|December 25, 2025
概括
血管内脑电脑接口 (EBCI) 为早期阿尔茨海默病 (AD) 诊断和治疗提供了一种最小入侵的解决方案. 这项技术有望改善阿兹海默症患者的认知功能和生活质量.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
背景情况:
- 阿尔茨海默病 (AD) 是老年人认知障碍的主要原因,给个人和社会带来了重大负担.
- 目前的AD治疗方法,包括胆酶抑制剂和记忆剂,可以缓解症状,但不能解决潜在的病理问题.
- 新兴的疗法,如抗粉样蛋白单克隆抗体,在阿尔茨海默病早期显示出有效性,但依赖于及时诊断,这仍然是一个挑战.
研究的目的:
- 审查血管内脑电脑接口 (EBCI) 的安全性和可行性,用于早期诊断和AD的神经调节治疗.
- 探索EBCI在针对特定大脑区域进行深度大脑刺激和利用外部神经反设备方面的潜力.
主要方法:
- 对AD中的EBCI应用现有文献的全面审查.
- 分析EBCI在早期诊断,深度大脑刺激 (例如,,Meynert的基底核) 和神经反中的作用.
- 检查AD患者EBCI的安全性和可行性数据.
主要成果:
- EBCI为综合性AD诊断和治疗提供了一种最少的侵入性方法.
- 具体应用包括早期检测,有针对性的深度大脑刺激和外部神经反.
- 该技术显示了改善阿兹海默症患者认知功能和独立生活的潜力.
结论:
- 通过早期干预和有针对性的神经调节,EBCI技术对促进AD管理具有重大前景.
- 预计未来的发展将涉及小型化,整合和探索更深层的大脑区域,以提高治疗效果.
- 需要进一步的研究,以充分确定EBCI在阿尔茨海默病临床实践中的安全性,有效性和长期益处.
更多相关视频
06:11Brain-Computer Interface-controlled Upper Limb Robotic System for Enhancing Daily Activities in Stroke Patients
Published on: April 18, 2025
1.5K
09:42Author Spotlight: Using Motor Imagery Brain-Computer Interface to Improve Motor and Cognitive Function in Stroke Patients
Published on: September 1, 2023
2.0K
相关概念视频
Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K